Results 101 to 110 of about 8,266,387 (310)

Smaller is better: nanobodies meet NMR

FEBS Letters, EarlyView.
Nanobodies are single‐domain antigen‐binding fragments derived from camelid heavy chain antibodies. Their small size, high stability, and exceptional specificity make nanobodies uniquely useful probes for NMR studies of protein dynamics, transient conformational states, and protein–protein interactions.
Oleg Y. Dmitriev
wiley   +1 more source

Potential of epigenetic therapies in the management of solid tumors

, 2015
Victor Valdespino,1 Patricia M Valdespino2 1Health Attention Department, Universidad Autónoma Metropolitana, Mexico; 2Bacterial Ecology and Epigenetics Laboratory, Universidad Nacional Autónoma de México, Mexico Abstract: Cancer is
Valdespino V, Valdespino PM
core  

Caspases compromise SLU7 and UPF1 stability and NMD activity during hepatocarcinogenesis

JHEP Reports
Background & Aims: The homeostasis of the cellular transcriptome depends on transcription and splicing mechanisms. Moreover, the fidelity of gene expression, essential to preserve cellular identity and function is secured by different quality control
Carla Rojo, María Gárate-Rascón, Miriam Recalde, Ane Álava, María Elizalde, María Azkona, Iratxe Aldabe, Elisabet Guruceaga, Amaya López-Pascual, M Ujue Latasa, Bruno Sangro, Maite G. Fernández-Barrena, Matías A. Ávila, María Arechederra, Carmen Berasain   +14 more
doaj   +1 more source

The role of miR‐335‐5p in the redifferentiation of BRAF p.V600E thyroid cancers

Molecular Oncology, EarlyView.
The BRAF p.V600E mutation promotes thyroid cancer dedifferentiation and radioiodine resistance. Using a network approach, we identified miR‐335‐5p as a key regulator of BRAF‐mutated thyroid tumors. Restoring miR‐335‐5p increased thyroid‐specific gene expression and iodine uptake in cells and organoids.
Valeria Pecce, Simone Bini, Marialuisa Sponziello, Giorgio Grani, Giulia Fiscon, Paola Paci, Lorenzo Farina, Rosa Falcone, Valentina Maggisano, Sebastiano Filetti, Cosimo Durante, Antonella Verrienti   +11 more
wiley   +1 more source

Metastasis on pause: How dormant tumor cells stay hidden within the tumor microenvironment and evade immune surveillance

Molecular Oncology, EarlyView.
Dormant cancer cells can hide in distant organs for years, evading treatment and the immune system. This review highlights how signals from the surrounding tissue and immune environment keep these cells inactive or trigger their reawakening. Understanding these mechanisms may help develop therapies to eliminate or control dormant cells and prevent ...
Kanishka Tiwary, Jose Javier Bravo‐Cordero   +1 more
wiley   +1 more source

Albumin-bound paclitaxel in solid tumors: clinical development and future directions

, 2015
Madappa N Kundranda,1 Jiaxin Niu21Medical Oncology, Banner MD Anderson Cancer Center, Gilbert, 2Department of Medical Oncology, Cancer Treatment Centers of America, Goodyear, Arizona, USA Abstract: Albumin-bound paclitaxel (nab-paclitaxel) is a solvent ...
Kundranda MN, Niu J
core  

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Poor prognosis and SATB1 overexpression in solid tumors: a meta-analysis

, 2018
Shengjie Wang,1,* Junjie Zeng,1,* Rui Xiao,2,* Guoxing Xu,3,* Gang Liu,1 Disheng Xiong,2 Yongzhi Ye,1 Borong Chen,1 Haibin Wang,2 Qi Luo,1 Zhengjie Huang1,2 1Department of Gastrointestinal Surgery, Xiamen Cancer Hospital, The First Affiliated Hospital of
Luo Q, Huang Z, Wang S, Zeng J, Xiong D, Wang H, Ye Y, Xu G, Chen B, Xiao R, Liu G   +10 more
core  

USP29‐regulated noncanonical stabilization of the hypoxia‐inducible factor‐α in aggressive prostate cancer

Molecular Oncology, EarlyView.
We identify USP29 as the only DUB mirroring CA9 expression, a marker of hypoxia and HIF pathway activation associated with PCA aggressiveness. USP29 stabilizes HIF‐1α and HIF‐2α via a noncanonical mechanism that is independent of PHD/pVHL activity yet relies on proteasomal regulation, establishing USP29 as a previously unrecognized regulator of hypoxic
Amelie S Schober, Leire Moreno‐Cugnon, Laura Martínez‐Pérez, Amaia Ercilla, Amaia Zabala‐Letona, Adrián Vicente‐Barrueco, Maider Fagoaga‐Eugui, Saioa Garcia‐Longarte, Blanca Calle‐Ciborro, Encarnación Pérez‐Andrés, Onintza Carlevaris, Sara Pozo, Isabel Mendizabal, Ugo Mayor, Arkaitz Carracedo, Violaine Sée, Edurne Berra   +16 more
wiley   +1 more source

Extramedullary hematopoiesis secondary to malignant solid tumors: a case report and literature review

, 2018
Youting Bao,1,2,* Zhichao Liu,2,3,* Meiying Guo,2,4 Butuo Li,2,5 Xindong Sun,2 Linlin Wang2 1Department of Oncology, Clinical College, Weifang Medical University, Weifang 261053, 2Department of Radiation Oncology, Shandong Cancer Hospital Affiliated to ...
Guo M, Liu Z, Bao Y, Li B, Sun X, Wang L
core